1 November 2023 in American Journal of Respiratory and Critical Care Medicine
Rationale: Intravenous plasma-purified alpha-1 antitrypsin (IV-AAT) has been used as therapy for alpha-1 antitrypsin deficiency (AATD) since 1987. Previous trials (RAPID and RAPID-OLE) demonstrated efficacy in preserving computed tomography of lung density but no effect on FEV1. This observational study evaluated 615 people with severe AATD from three countries with socialized health care (Ireland, Switzerland, and Austria), where access to standard medical care was equal but access to IV-AAT was not. Objectives: To assess the real-world longitudinal effects of IV-AAT. Methods: Pulmonary function and mortality data were utilized to perform longitudinal analyses on registry participants with severe AATD. Measurements and Main Results: IV-AAT confers a survival benefit in severe AATD (P < 0.001). We uncovered two distinct AATD phenotypes based on an initial respiratory diagnosis: lung index and non–lung index. Lung indexes demonstrated a more rapid FEV1 decline between the ages of 20 and 50 and subsequently entered a plateau phase of minimal decline from 50 onward. Consequentially, IV-AAT had no effect on FEV1 decline, except in patients with a Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2 lung index. Conclusions: This real-world study demonstrates a survival advantage from IV-AAT. This improved survival is largely decoupled from FEV1 decline. The observation that patients with severe AATD fall into two major phenotypes has implications for clinical trial design where FEV1 is a primary endpoint. Recruits into trials are typically older lung indexes entering the plateau phase and, therefore, unlikely to show spirometric benefits. IV-AAT attenuates spirometric decline in lung indexes in GOLD stage 2, a spirometric group commonly outside current IV-AAT commencement recommendations.
15 April 2024 in American Journal of Respiratory and Critical Care Medicine
9 September 2023 in European Respiratory Journal
Introduction: Intravenous plasma-purified alpha-1 antitrypsin (IV-AAT) has been shown to be biochemically effective in treating AAT deficiency (AATD) since the 1980s. The RAPID-OLE study demonstrated a beneficial effect of IV-AAT on preservation of lung parenchymal density, as measured by CT lung density, a marker of emphysema and disease progression. Methods: Our study followed 615 severe AATD patients over a mean of 58 months (max of 286 months) across 3 countries with socialised healthcare - Ireland, Switzerland and Austria but with differing access to IV-AAT. Spirometry and diffusion capacity were measured at intervals over this timespan. Results: Kaplan-Meier survival analysis over 25 years demonstrated a survival benefit from receiving IV-AAT compared to those not receiving IV-AAT (p = 0.00076) (figure 1). There was no appreciable difference in rate of decline of lung function between those receiving IV-AAT and those who did not. Conclusion: Our three-country observational study demonstrates that the benefit of IV-AAT may not be appreciable when using lung function as a marker of disease progression in AATD and that IV-AAT has benefits beyond preserving lung function decline. Figure 1: Kaplan-Meier survival analysis stratified by augmentation therapy status across all three countries.